Evaluation of Sex Hormone Levels in Benign Prostatic Hyperplasia Patients Treated with 5 Alpha-Reductase Inhibitor (Finasteride) in Amara City, Iraq

    March 2020 in “ Baghdad Science Journal ”
    Hashim Et al.
    Studysummary This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on bsj.uobaghdad.edu.iq →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Endocrine Control of Benign Prostatic Hyperplasia Andrology · 2016
    2. Finasteride Use in the Male Infertility Population: Effects on Semen and Hormone Parameters Fertility and Sterility · 2013
    3. Effect of Finasteride on Lipid Profile in Individuals with Androgenetic Alopecia African Journal of Pharmacy and Pharmacology · 2013
    4. Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone The Journal of Clinical Endocrinology and Metabolism · 2004
    5. The Effect of Finasteride in Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1992

    Related research 7

    1. Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients After Finasteride Treatment for a Year Journal of The American Academy of Dermatology · 2021
    2. 5-Alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy, and Safety Dermatologic Therapy · 2020
    3. The Effects of Finasteride on Scalp Skin and Serum Androgen Levels in Men with Androgenetic Alopecia Journal of The American Academy of Dermatology · 1999
    4. A Model for the Turnover of Dihydrotestosterone in the Presence of the Irreversible 5α-Reductase Inhibitors GI198745 and Finasteride Clinical Pharmacology & Therapeutics · 1998
    5. Effect of MK-386, a Novel Inhibitor of Type 1 5 Alpha-Reductase, Alone and in Combination with Finasteride, on Serum Dihydrotestosterone Concentrations in Men The Journal of Clinical Endocrinology and Metabolism · 1996
    6. Effect of MK-386, a Novel Inhibitor of Type 1 5 Alpha-Reductase, Alone and in Combination with Finasteride, on Serum Dihydrotestosterone Concentrations in Men The Journal of Clinical Endocrinology and Metabolism · 1996
    7. The Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Scalp Skin Testosterone and Dihydrotestosterone Concentrations in Patients With Male Pattern Baldness The Journal of Clinical Endocrinology and Metabolism · 1994